Transcriptional regulation of cholesterol 7 alpha-hydroxylase mRNA by conjugated bile acids in primary cultures of rat hepatocytes. 1993

R T Stravitz, and P B Hylemon, and D M Heuman, and L R Hagey, and C D Schteingart, and H T Ton-Nu, and A F Hofmann, and Z R Vlahcevic
Section of Gastroenterology, McGuire Veterans Administration Medical Center, Richmond, Virginia.

The role of bile acids in the regulation of cholesterol 7 alpha-monooxygenase (EC 1.14.13.17) was characterized using primary cultures of rat hepatocytes supplemented with dexamethasone and thyroxine. Taurocholate and taurodeoxycholate (50 microM) repressed cholesterol 7 alpha-hydroxylase mRNA to 44 +/- 9 and 52 +/- 4%, respectively, of control values. Repression by these natural, relatively hydrophobic bile acids was concentration dependent, with an IC50 of about 50 microM, and time dependent with a t1/2 for repression of 22 h. In contrast, two natural hydrophilic bile acids, tauroursodeoxycholate and taurohyodeoxycholate, had no effect on cholesterol 7 alpha-hydroxylase mRNA levels. Taurochenodeoxycholate and taurolithocholate also had no effect, but these hydrophobic bile acids were rapidly hydroxylated to more hydrophilic bile acids. Hydrophilic bile acid analogues (nor (C23) bile acids and beta-hydroxy epimers) repressed cholesterol 7 alpha-hydroxylase mRNA less potently than their corresponding and more hydrophobic C24 or alpha-hydroxy derivatives. Cholesterol 7 alpha-hydroxylase specific activity was decreased by taurocholate or taurodeoxycholate (50 microM) to 26 +/- 9 and 56 +/- 3% of control, respectively; its transcriptional activity was repressed to 52 +/- 5% of control by taurocholate (50 microM). The addition of cholesterol or the induction of cholesterol biosynthesis did not influence repression of cholesterol 7 alpha-hydroxylase mRNA levels by taurocholate. Based on several lines of evidence, cAMP was not involved in bile acid-induced repression. In rat hepatocytes cultured under conditions in which cholesterol 7 alpha-hydroxylase gene expression is maintained at in vivo levels, hydrophobic bile acids repress this enzyme at the level of gene transcription independently of cholesterol availability.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007770 L-Lactate Dehydrogenase A tetrameric enzyme that, along with the coenzyme NAD+, catalyzes the interconversion of LACTATE and PYRUVATE. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist. Lactate Dehydrogenase,Dehydrogenase, L-Lactate,Dehydrogenase, Lactate,L Lactate Dehydrogenase
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002790 Cholesterol 7-alpha-Hydroxylase A membrane-bound cytochrome P450 enzyme that catalyzes the 7-alpha-hydroxylation of CHOLESTEROL in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP7, converts cholesterol to 7-alpha-hydroxycholesterol which is the first and rate-limiting step in the synthesis of BILE ACIDS. CYP7,CYP7A,Cytochrome P-450 CYP7,CYP 7,CYP 7A,Cholesterol 7-alpha-Monooxygenase,Cholesterol 7alpha-Hydroxylase,Cholesterol-7-Hydroxylase,Cytochrome P450 7,Cholesterol 7 Hydroxylase,Cholesterol 7 alpha Hydroxylase,Cholesterol 7 alpha Monooxygenase,Cholesterol 7alpha Hydroxylase,Cytochrome P 450 CYP7
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001647 Bile Acids and Salts Steroid acids and salts. The primary bile acids are derived from cholesterol in the liver and usually conjugated with glycine or taurine. The secondary bile acids are further modified by bacteria in the intestine. They play an important role in the digestion and absorption of fat. They have also been used pharmacologically, especially in the treatment of gallstones. Bile Acid,Bile Salt,Bile Salts,Bile Acids,Acid, Bile,Acids, Bile,Salt, Bile,Salts, Bile
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

R T Stravitz, and P B Hylemon, and D M Heuman, and L R Hagey, and C D Schteingart, and H T Ton-Nu, and A F Hofmann, and Z R Vlahcevic
March 1993, The Biochemical journal,
R T Stravitz, and P B Hylemon, and D M Heuman, and L R Hagey, and C D Schteingart, and H T Ton-Nu, and A F Hofmann, and Z R Vlahcevic
June 1995, Journal of lipid research,
R T Stravitz, and P B Hylemon, and D M Heuman, and L R Hagey, and C D Schteingart, and H T Ton-Nu, and A F Hofmann, and Z R Vlahcevic
August 1989, The Biochemical journal,
R T Stravitz, and P B Hylemon, and D M Heuman, and L R Hagey, and C D Schteingart, and H T Ton-Nu, and A F Hofmann, and Z R Vlahcevic
December 1969, Archives internationales de physiologie et de biochimie,
R T Stravitz, and P B Hylemon, and D M Heuman, and L R Hagey, and C D Schteingart, and H T Ton-Nu, and A F Hofmann, and Z R Vlahcevic
October 1979, La Revue du praticien,
R T Stravitz, and P B Hylemon, and D M Heuman, and L R Hagey, and C D Schteingart, and H T Ton-Nu, and A F Hofmann, and Z R Vlahcevic
February 1991, The Journal of biological chemistry,
R T Stravitz, and P B Hylemon, and D M Heuman, and L R Hagey, and C D Schteingart, and H T Ton-Nu, and A F Hofmann, and Z R Vlahcevic
January 1995, The Biochemical journal,
R T Stravitz, and P B Hylemon, and D M Heuman, and L R Hagey, and C D Schteingart, and H T Ton-Nu, and A F Hofmann, and Z R Vlahcevic
July 1990, The Journal of biological chemistry,
R T Stravitz, and P B Hylemon, and D M Heuman, and L R Hagey, and C D Schteingart, and H T Ton-Nu, and A F Hofmann, and Z R Vlahcevic
February 1995, Hepatology (Baltimore, Md.),
R T Stravitz, and P B Hylemon, and D M Heuman, and L R Hagey, and C D Schteingart, and H T Ton-Nu, and A F Hofmann, and Z R Vlahcevic
June 1993, Journal of lipid research,
Copied contents to your clipboard!